SCHEMBL6735203

SCHEMBL6735203

CCOC(Cc1ccc(OCCC=C2c3ccccc3OCOc3ccccc32)cc1)C(=O)O

nearest known ligand 0.85

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARG P37231 17/20 0.85
PPARA Q07869 16/20 0.85
PPARD Q03181 7/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6731283 0.96 PPARG (0.82) PPARGPPARAPPARD
SCHEMBL6731527 0.94 PPARG (0.75) PPARGPPARAPPARD
SCHEMBL6731007 0.92 PPARG (1.00) PPARGPPARAPPARD
SCHEMBL6731002 0.92 PPARG (1.00) PPARGPPARAPPARD
SCHEMBL6737030 0.92 PPARG (0.72) PPARGPPARAPPARD
SCHEMBL6740441 0.91 PPARG (0.74) PPARGPPARAPPARD
SCHEMBL6740565 0.90 PPARG (0.70) PPARGPPARAPPARD
SCHEMBL6737276 0.90 PPARG (1.00) PPARGPPARAPPARD
SCHEMBL7602275 0.88 PPARG (0.93) PPARGPPARAPPARD
SCHEMBL6734839 0.88 PPARG (0.93) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020115654-A1 New compounds, their preparation and use JEPPESEN LONE (DK) 2002-08-22 US claimed
US-6683111-B2 SUCH AS 2-ETHOXY-3-(4-(2-XANTHEN-9-YLIDENE-ETHOXY)-PHENYL)-PROPIONIC ACID; FOR TREATING CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; TREATMENT OF DIABETES/OBESITY NOVO NORDISK A/S (DK) 2004-01-27 US disclosed
US-20020115654-A1 New compounds, their preparation and use JEPPESEN LONE (DK) 2002-08-22 US disclosed
US-6353018-B1 Compounds, their preparation and use NOVO NORDISK A/S (DK) 2002-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115654-A1 New compounds, their preparation and use PPARG, PPARD, PPARA PPARG 1/4885PPARA 3/4885PPARD 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.